Table 2

Diagnosis or indication associated with prescription of cyproterone acetate/ethinylestradiol and two combined oral contraceptives, as determined from medical records

Cyproterone acetate/ethinylestradiolDrospirenone/ethinylestradiolLevonorgestrel/ethinylestradiol
Diagnosis/indication2002 (n=1595)2010 (n=1599)2002 (n=1009)2010 (n=3373)2002 (n=5632)2010 (n=9633)
Acne813 (51.0)1266 (79.2)119 (11.8)831 (24.6)471 (8.4)868 (9.0)
Hirsutism48 (3.0)80 (5.0)2 (0.2)16 (0.5)2 (0.04)9 (0.1)
Polycystic ovary syndrome70 (4.4)46 (2.9)7 (0.7)38 (1.1)8 (0.1)26 (0.3)
Oligomenorrhoea16 (1.0)11 (0.7)15 (1.5)26 (0.8)50 (0.9)62 (0.6)
Infertility/anovulation1 (0.1)0 (0)0 (0)2 (0.1)2 (0.04)8 (0.1)
Alopecia15 (0.9)4 (0.3)4 (0.4)13 (0.4)18 (0.3)34 (0.4)
Gynaecological disorders*107 (6.7)55 (3.4)160 (15.9)531 (15.7)815 (14.5)1958 (20.3)
Contraception525 (32.9)137 (8.6)702 (69.6)1916 (56.8)4266 (75.7)6668 (69.2)
 Read code for contraception472 (89.9)130 (94.9)643 (91.6)1752 (91.4)3711 (87.0)6107 (91.6)
 No Read code†53 (10.1)7 (5.1)59 (8.4)164 (8.6)555 (13.0)561 (8.4)
  • *Gynaecological disorders include dysmenorrhoea, menorrhagia, irregular menstruation, premenstrual syndrome, uterine fibroids, endometriosis and dyspareunia.

  • †In the absence of a Read code indicating use for contraception or to treat hormone-responsive conditions, women were assumed to have been using the product for contraception.